Harry Simeonidis
About Harry Simeonidis
Harry Simeonidis, 56, is President and Chief Executive Officer of Intelligent Bio Solutions Inc. (INBS) and has served in this role since October 2022; he previously held multiple leadership positions at INBS including President (2017–2021), CEO (Jan 2020–Oct 2021), and President Asia Pacific, Sales & Marketing (Oct 2021–Oct 2022) . He brings more than 27 years of senior management experience across healthcare, pharmaceutical, and life sciences in the APAC region, including CEO of GE Healthcare Australia & New Zealand (2003–2012) and General Manager of Surgery, APAC at GE Healthcare (2013–Apr 2015), with subsequent roles in consulting and as General Manager of FarmaForce Limited (2017–2019) . The latest proxy does not disclose TSR, revenue growth, or EBITDA growth for his tenure; executive compensation is paid via INBS’s Australian subsidiary and denominated in AUD, converted to USD at disclosed rates .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Intelligent Bio Solutions Inc. | President & CEO | Oct 2022–Present | Leads day-to-day management and corporate strategy in regulated medical device/product sectors . |
| Intelligent Bio Solutions Inc. | President; Director | Sep 2017–Oct 2021 | Senior leadership and board service during transformation period . |
| Intelligent Bio Solutions Inc. | Chief Executive Officer | Jan 2020–Oct 2021 | Executive leadership prior to interim CEO transition . |
| Intelligent Bio Solutions Inc. | President Asia Pacific, Sales & Marketing | Oct 2021–Oct 2022 | Regional commercialization and sales leadership . |
| GE Healthcare (Australia & New Zealand) | CEO | 2003–2012 | Led country P&L and operations in medical technology . |
| GE Healthcare (APAC) | General Manager, Surgery | 2013–Apr 2015 | Regional leadership for surgical portfolio . |
| Private Consulting (Australia) | Principal/Consultant | Apr 2015–Mar 2017 | Advisory services to healthcare sector . |
| FarmaForce Limited (ASX) | General Manager | Mar 2017–Dec 2019 | Commercial leadership at listed healthcare company . |
External Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| FarmaForce Limited (ASX) | General Manager | Mar 2017–Dec 2019 | Led commercial operations at a listed Australian healthcare company . |
Fixed Compensation
Multi-year Executive Compensation (USD)
| Metric | FY 2024 | FY 2025 |
|---|---|---|
| Salary | $293,390 | $366,250 |
| Bonus | $107,522 | $0 |
| Stock Awards (Grant-date fair value) | $0 | $56,945 |
| All Other Compensation | $45,710 | $59,476 |
| Total | $446,622 | $482,671 |
Current Fixed Pay Elements (as of Jun 30, 2025)
| Element | Detail |
|---|---|
| Base Salary | Increased from $366,800 to $379,900 effective Jun 30, 2025 (Spot Rate basis) . |
| Superannuation | Mandatory Australian defined contribution at 12% of salary (11.5% during FY25) . |
| Car Allowance | Annual car allowance $15,720 (Spot Rate basis); FY24 allowance disclosed at $15,735 . |
Performance Compensation
| Incentive Type | Metric | Weighting | Target | Actual FY 2025 | Payout | Vesting / Notes |
|---|---|---|---|---|---|---|
| Annual Cash Bonus | Company objectives | 50% of bonus | Up to 20% of base salary | Not disclosed | $0 (no bonus paid in FY25) | Determined by Compensation Committee; objectives not disclosed . |
| Annual Cash Bonus | Individual objectives | 50% of bonus | Up to 20% of base salary | Not disclosed | $0 (no bonus paid in FY25) | Mutually agreed employee objectives or as otherwise determined . |
| Equity Awards (2019 LTIP) | RSU/Stock awards | N/A | $56,945 grant-date fair value (ASC 718) | Not disclosed | N/A | As of Jun 30, 2025, all outstanding stock awards fully vested; no outstanding awards remain . |
The 2019 Long Term Incentive Plan allows RSUs, options, SARs, and other stock-based awards, potentially with performance conditions; committee sets vesting schedules and may accelerate vesting under certain change-of-control scenarios .
Equity Ownership & Alignment
| Ownership Item | Detail |
|---|---|
| Shares Beneficially Owned | 40,408 shares . |
| % of Shares Outstanding | Less than 1% (outstanding shares: 9,028,712 as of Sep 11, 2025) . |
| Vested vs. Unvested | All outstanding stock awards were fully vested at FY-end 2025; no outstanding equity awards remain . |
| Options (Exercisable/Unexercisable) | Not disclosed; no outstanding equity awards at FY-end 2025 . |
| Shares Pledged as Collateral | Not disclosed; company insider trading policy prohibits hedging without prior approval; pledging not specifically disclosed . |
| Stock Ownership Guidelines | Not disclosed in proxy . |
| Equity Plan Pool | 1,192,655 shares available for issuance under 2019 Plan as of Sep 11, 2025 . |
Employment Terms
| Term | Provision |
|---|---|
| Employment Agreement | With Intelligent Bio Solutions (APAC) Pty Ltd; original dated Jun 27, 2022; amended Jun 30, 2025 . |
| Termination Notice | Six months’ notice by either party; immediate termination for cause under specified misconduct clauses . |
| Non-compete / Restricted Period | Tiered restricted period from 24 months down to 1 month depending on enforceability; expanded scope to prohibit direct/indirect involvement with competitors during restricted period and within restricted area . |
| Severance (Without Cause) | Cash payment equal to 100% of potential bonus (regardless of performance) payable with similarly situated bonuses; immediate full vesting of all outstanding equity awards as of termination date (subject to tax withholding) . |
| Change-in-Control (CIC) Severance | If termination without cause occurs in connection with or following a CIC: cash equal to 2x annual base salary plus an additional cash payment equal to 100% of potential bonus (subject to tax withholdings) . |
| CIC Definition | Broadly includes acquisition >20% of voting stock, certain mergers/consolidations with voting power change, sale of all/substantially all assets, or board majority change; excludes increases due to company repurchases . |
| Equity Award Acceleration | For non-approved change-of-control: automatic full acceleration and 100% target achievement for performance goals; for approved transactions: committee may accelerate, cash-out at repurchase value, or terminate performance periods and pay based on attainment . |
| Clawback Policy | Dodd-Frank recoupment policy effective Oct 2, 2023; recovers erroneously awarded incentive compensation over prior three completed fiscal years after a required restatement . |
| Hedging Policy | Prohibits hedging transactions in company securities without prior approval; insider trading compliance emphasized . |
| Superannuation | Employer contributions at 12% of salary (11.5% during FY25) to Australian defined contribution funds; employee-selected approved fund . |
Investment Implications
- Pay mix shifted toward fixed compensation in FY25: salary increased and no annual bonus was paid; equity award value was modest ($56,945) and all awards were fully vested by year-end, reducing future scheduled vesting overhang and near-term insider selling pressure from vest releases .
- Severance and CIC protections are generous (double-trigger: 2x salary + 100% potential bonus plus immediate vesting), which may increase potential change-of-control costs but provide leadership retention through uncertainty; non-compete terms tightened with broader scope and longer potential restricted periods up to 24 months (jurisdiction-dependent), improving post-exit protection for INBS .
- Equity ownership alignment is limited by a small personal stake (<1%); absence of disclosed ownership guidelines and no pledging disclosures reduce visibility into alignment, though hedging is restricted and a formal recoupment policy supports governance and pay-for-performance integrity .
- Biography indicates deep APAC healthcare operating experience and prior GE Healthcare leadership, which aligns with INBS’s regulated product strategy; however, the proxy does not disclose TSR or operational performance metrics tied to compensation outcomes, indicating limited transparency into pay-for-performance calibration for FY25 .